Bausch + Lomb Co. (NYSE:BLCO) Given Average Recommendation of “Hold” by Brokerages

Bausch + Lomb Co. (NYSE:BLCO) has been given an average recommendation of “Hold” by the thirteen ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $20.25.

A number of research analysts have weighed in on the stock. Evercore ISI raised shares of Bausch + Lomb from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $19.00 to $25.00 in a research note on Tuesday, October 15th. Royal Bank of Canada dropped their price target on shares of Bausch + Lomb from $23.00 to $22.00 and set an “outperform” rating on the stock in a research report on Wednesday, January 29th. Bank of America reissued an “underperform” rating and set a $18.00 price objective on shares of Bausch + Lomb in a report on Thursday, December 12th. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Bausch + Lomb in a report on Thursday, December 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st.

Bausch + Lomb Price Performance

Shares of NYSE:BLCO opened at $17.74 on Thursday. The stock’s 50 day moving average is $18.16 and its 200-day moving average is $18.17. Bausch + Lomb has a twelve month low of $13.16 and a twelve month high of $21.69. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $6.25 billion, a price-to-earnings ratio of -16.89, a PEG ratio of 2.30 and a beta of 0.46.

Hedge Funds Weigh In On Bausch + Lomb

Several institutional investors have recently bought and sold shares of the company. Blue Trust Inc. raised its stake in shares of Bausch + Lomb by 68.3% in the fourth quarter. Blue Trust Inc. now owns 2,474 shares of the company’s stock valued at $48,000 after buying an additional 1,004 shares during the period. FNY Investment Advisers LLC bought a new stake in Bausch + Lomb in the 4th quarter valued at about $72,000. Squarepoint Ops LLC purchased a new stake in Bausch + Lomb during the second quarter valued at about $173,000. Gordian Capital Singapore Pte Ltd bought a new position in Bausch + Lomb during the third quarter worth about $289,000. Finally, Polar Asset Management Partners Inc. bought a new position in Bausch + Lomb during the third quarter worth about $289,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.